EWA
MLYS icon

EverSource Wealth Advisors’s Mineralys Therapeutics MLYS Stock Holding History

EverSource Wealth Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19K Sell
44
-152
-78% -$4.17K ﹤0.01% 3911
2026
Q1 		$5.31K Buy
196
+42
+27% +$1.23K ﹤0.01% 3238
2025
Q4 		$5.59K Buy
154
+2
+1% +$80 ﹤0.01% 3085
2025
Q3 		$5.76K Sell
152
-205
-57% -$4.43K ﹤0.01% 3095
2025
Q2 		$4.83K Buy
357
+341
+2,131% +$4.94K ﹤0.01% 3173
2025
Q1 		$254 Buy
+16
New +$184 ﹤0.01% 3646

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EverSource Wealth Advisors's MLYS Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Mineralys Therapeutics (MLYS) stake by 78% in Q2 2026, selling an estimated $4.17K and leaving 44 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #3911.

EverSource Wealth Advisors first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.76K in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • EverSource Wealth Advisors held 44 shares of Mineralys Therapeutics worth $1.19K as of Q2 2026.
  • EverSource Wealth Advisors sold 152 Mineralys Therapeutics shares in Q2 2026, an estimated $4.17K.
  • Mineralys Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3911 holding.
  • EverSource Wealth Advisors first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • EverSource Wealth Advisors's Mineralys Therapeutics position peaked at $5.76K in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.